Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2012

View Archived Issues

Buprenorphine/naltrexone combination evaluated in experimental cocaine dependence

Scientists identify new predictors of severe obesity

Nanofiber/VEGF therapy shows potential for use after myocardial infarction

New cause identified of severe X-linked retinitis pigmentosa

CHDI Foundation presents novel HDAC4 inhibitors

Eisai divulges new PGE2/EP4 receptor signaling suppressors

Research at Zafgen yields new candidate obesity drugs

Lykera Biomed reports novel S100-P-directed antibodies

New potential ocular medications designed in Korea

Novel candidate cancer gene therapies developed in U.S.

U.S. university receives grant to set up translational research center

Enrollment complete in two Reolysin studies

Nectid repurposes agomelatine for pain and autism

FDA approves sNDA for Tradjenta

SBIR grant supports CMV antibody program

NIAID supports tuberculosis drug discovery software development

NICE publishes draft guidance on denosumab

Lenvatinib obtains orphan drug status

AbGenomics gains FDA clearance for trial of candidate drug for autoimmune disease

New formulation of palivizumab approved in Japan

FDA clears phase I trial of H5N1 vaccine with GLA vaccine adjuvant

Japanese approval for new dosage of Amaryl

New indication approved for Neoral and Sandimmun in Japan

New phase I study of F-351 begins in China

U.K. alliance set to launch AZD-8931 combination trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...